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INTRODUCTION
There has been a renewed interest in suppressor, or reg-
ulatory, T-cells because new technologies and reagents allow
for more specific identification of such cells. Regulatory
T-cells include several phenotypes. One population that has
received a great deal of attention consists of CD4+ cells that
constitutively express CD25, the α-chain of the interleukin
(IL)-2 receptor. In mice, 5% to 10% of mature CD4+ T-cells
express CD25 [1,2]. Similar cells have been reported in
humans [3-6]. These cells acquire their phenotypic charac-
teristics and immunosuppressive function in the thymus
[7,8], but little is known about how this acquisition occurs.
Experimental data have suggested that CD28-B7 and
CD40L-CD40 interactions are important in the generation
of CD4+CD25+ cells because CD4+CD25+ cell numbers are
signiﬁcantly reduced in CD28-deﬁcient and CD40-deﬁcient
mice [9,10]. Despite their small numbers, CD4+CD25+ cells
have been shown by several investigators to exhibit potent
immunosuppressive functions both in vitro and in vivo
[11,12]. These cells play an important role in several set-
tings, including autoimmune disease [1,13], allograft toler-
ance [14-16], syngeneic graft-versus-host disease (GVHD)
[17], allergy [18], and tumor immunity [19-21]. Adoptively
transferred CD4+CD25+ cells can also suppress GVH reac-
tivity [15,22].
We previously described the presence of thymus-derived
donor T-cells that suppress GVH reactions induced by
post–bone marrow transplantation (BMT) infusion of donor
T-cells [23], a form of adoptive immunotherapy typically
referred to as donor leukocyte infusion (DLI) therapy. The
regulatory T-cells were Thy1+ and αβ T-cell receptor
(TCR)+ and consisted of 2 subpopulations: CD4+CD8–
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ABSTRACT
We have previously identified donor-derived Thy1+ αβ T-cell receptor (TCR)+ CD4+CD8– regulatory T-cells that
suppress GVH reactivity induced by donor leukocyte infusion (DLI) after BMT. These cells develop in the recipient
thymus and may play a role in the maintenance of donor-host tolerance after allogeneic BMT. In the present study,
we sought to further characterize the T-cells responsible for the regulatory cell activity in our model. Lethally irra-
diated recipient AKR mice (H-2k) received transplants of BM from CD25-deficient (–/–) C57BL/6 mice (H-2b).
Recipients of CD25-deficient BM developed more severe GVHD after DLI than did recipients of normal BM, a
result that indirectly suggests that CD4+CD25+ regulatory T-cells are important to the suppression of GVH reactiv-
ity after allogeneic BMT. GVHD was accompanied by mortality, body weight loss, and elevated percentages of
T-cells from the DLI in the peripheral blood in mice that received CD25-deficient BM compared to mice that
received normal BM. Both CD40-CD40L and CD28-B7 costimulatory pathways have been implicated in the gener-
ation of CD25+ regulatory T-cells. Therefore, we tested whether deficiency in either of these pathways affected the
activity of donor BM–derived regulatory T-cells. The absence of CD40L did not affect the regulatory T-cells (ie,
recipient mice were still protected from DLI-induced GVHD). In contrast, use of marrow from CD28-deficient
mice resulted in complete loss of suppression of GVH reactivity. Thus, CD28 but not CD40L was critical for the
generation and/or activation of immunoregulatory T-cells that suppressed GVHD induced by DLI. Together, the
results of these experiments suggest that CD4+CD25+ regulatory T-cells suppress GVH reactivity after BMT and
that CD28 expression is indispensable for the generation of these cells.
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T-cells and CD4–CD8– double-negative (DN) T-cells [23].
We hypothesized that the CD4+ population consists of
CD4+CD25+ regulatory T-cells. In the present study, we
demonstrate that CD25+ T-cells play an important role in
suppression of GVH reactivity after DLI and provide indi-
rect evidence that these cells are the CD4+ regulatory T-cells
previously identiﬁed by us. The results presented here also
further implicate CD4–CD8– DN cells as regulatory cells in
our DLI model. Thymus-derived regulatory T-cells may
help in the establishment and maintenance of donor-host
tolerance after allogeneic BMT.
MATERIALS AND METHODS
Mice
Mice aged 4 to 6 weeks of the strains AKR/J (H-2k,
Thy1.1+); AKR/Cum (H-2k, Thy1.2+); C57BL/6 (H-2b,
Thy1.2+); B6.PL-Thy1a (H-2b; Thy1.1+); C57BL/6-
Cd28tm1Mak (CD28 knock-out [KO])); C57BL/6-Tnfsf5tm1Imx
(CD40L KO); and C57BL/6-Cd4tm1MAK (CD4 KO) were
obtained from Jackson Laboratories (Bar Harbor, Maine).
A C57BL/6-IL2ratm1Dw (CD25 KO) heterozygote breeding
pair was also obtained from Jackson Laboratories, and the
offspring were screened for homozygosity using poly-
merase chain reaction in a protocol provided by Jackson
Laboratories. All animals were housed and cared for in the
Medical College of Wisconsin’s Animal Resource Center
(Milwaukee, WI).
Experimental Design and Transplantation Protocols
The basic experimental design for these studies is shown
in Figure 1. AKR mice (AKR/J or AKR/Cum) were condi-
tioned for BMT with a lethal dose of 1100 cGy total body
irradiation (TBI) using a small-animal cesium irradiator
(Shepherd Mark I; JL Shepherd, San Fernando, CA). The
irradiated mice underwent transplantation 18 hours later by
intravenous (IV) injection with 107 T-depleted BM cells
from C57BL/6 donor mice. The recipient mice were fully
engrafted with donor hematopoietic cells, and by 3 weeks
after BMT, all mononuclear cells in the lymphoid organs
were of donor origin except for the T-cells, which were a
mixture of donor and residual host T-cells (data not shown).
The thymuses became fully donor engrafted and produced
new mature donor T-cells, including the regulatory T-cells
identiﬁed in our previous studies [23]. DLI (3 × 107 donor
splenocytes) given to these recipients on day 28 after BMT
induced only mild GVHD. In contrast, if donor regulatory
T-cells were eliminated before the DLI, the recipients devel-
oped severe and lethal GVHD [23]. Selective elimination of
donor regulatory T-cells was accomplished by treating mice
before DLI with in vivo–depleting anti-Thy1.2 monoclonal
antibody (MoAb) (clone 30-H12; American Type Culture
Collection, Rockville, MD). This strategy eliminated regula-
tory T-cells, and Thy1.1+ C57BL/6 (B6.PL-Thy1a) spleno-
cytes could be given as DLI without concern that they would
be depleted by the anti-Thy1.2 MoAb.
The goal of the current study was to determine whether
elimination of CD25, CD28, or CD40L molecules on the
newly generated host-thymus–derived donor T-cells
affected the regulatory T-cell activity. To eliminate these
molecules, recipient AKR mice received transplants of BM
from CD25-KO, CD28-KO, or CD40L-KO mice. We
hypothesized that if any of these molecules were involved in
generation and/or activation of the regulatory T-cells, then
mice that received transplants of BM deﬁcient for the par-
ticular molecule would develop severe GVHD after DLI
(with 3 × 107 splenocytes from normal mice). In those
experiments in which mice were given transplants of CD4-
KO BM (to confirm previous results), a higher dose of
donor cells (6 × 107 splenocytes) was given as DLI on day 35
after BMT. Control groups of mice received transplants of
BM from normal C57BL/6 donors.
For experiments in which recipients received transplants
of CD25 KO BM, the BMT protocol was modiﬁed because
of engraftment problems. Recipient AKR/Cum mice
(Thy1.2+) were conditioned with lethal TBI and injected
intraperitoneally (IP) with 1 mg of anti-Thy1.2 MoAb on
the day of BMT to further suppress host-versus-graft reac-
tivity. This approach resulted in consistent donor engraft-
ment after BMT with CD25-KO BM.
To obtain BM, femurs and tibias were collected from
C57BL/6 normal and KO donor mice. The bones were
Figure 1. Experimental design. To test the roles of CD25+, CD4+, CD28+, and CD40L+ regulatory T-cells in the suppression of GVHD after DLI,
the indicated genetically deﬁcient (KO) mice were used as BM donors. Thy1.2+ regulatory T-cells are produced de novo from donor BM–derived
precursors in the reconstituted host thymus [23].
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flushed with Dulbecco modified Eagle culture medium.
The BM cells were treated with anti-Thy1.2 MoAb (clone
30-H12) and complement (Low-Tox-M; Accurate Chemical
and Scientiﬁc Corp, Westbury, CT) to remove T-cells. For
DLI, splenocytes were collected from healthy Thy1.1+
C57BL/6 (B6.PL-Thy1a) mice.
Phenotypic Analysis
On days 24 through 27 after BMT, blood samples were
obtained from all mice that underwent transplantation in
each experiment to assess engraftment status. Whole blood
samples collected in EDTA were stained with a ﬂuoroscein
isothiocyanate (FITC)-conjugated donor major histocompat-
ibility complex (MHC) class I–specific MoAb (FITC-anti-
H2Kb) in conjunction with a phycoerythrin (PE)-conjugated
B-cell–speciﬁc MoAb (PE–anti-B220). Red cells were elimi-
nated with ﬂuorescence-activated cell-sorting (FACS) lysing
solution (BD Biosciences, San Jose, CA), and the stained
mononuclear cells were ﬁxed in 1% paraformaldehyde.
In some experiments, blood samples were collected 7 to
10 days after DLI to determine the percentage of DLI-
derived donor T-cells. To detect these cells, the blood
samples were stained with FITC–anti-H2Kb plus PE–anti-
Thy1.1. This staining method allowed us to distinguish
DLI-derived donor T-cells (H-2b, Thy1.1) from BM-
derived donor T-cells (H-2b, Thy1.2).
Splenocytes from some BM donors were collected to
assess CD4+CD25+ T-cell content. These cells were stained
with FITC–anti-CD4 and PE–anti-CD25.
For immune reconstitution studies, splenocytes isolated
from BM chimeras on day 28 after BMT were stained with
FITC–anti-H2Kk (recipient MHC class I-specific) or
FITC–anti-H2Kb (donor MHC class I-speciﬁc) in combina-
tion with PE–anti-B220, PE–anti-CD4, PE–anti-CD8, or
PE–anti–Mac-1 to detect B-cells, T-cells, and monocytes of
donor and host origin. In some experiments, the splenocytes
were analyzed for CD4+CD25+ T-cell content by 3-color
flow cytometry using FITC–anti-Thy1.1 (host T-cells) or
Figure 2. Thy1+ cells of donor origin suppress GVH reactivity after DLI. Lethally irradiated recipient AKR mice received transplants of
107 C57BL/6 BM cells and were then randomized to receive no further treatment (BM Only), DLI with 3 × 107 Thy1.1+ donor (B6.PL- Thy1a)
spleen cells on day 28 post-BMT (BM + DLI), or treatment with 0.5 to 1 mg of anti-Thy1.2 MoAb IP 4 and 2 days before DLI to deplete regulatory
T-cells (BM + α-Thy1.2 + DLI). The mice were followed for survival (A) and body weight change (B). The survival curves are the combined data of
20 independent experiments. Body weight curves are the data from 1 representative experiment.
B. D. Johnson et al.
528
FITC–anti-Thy1.2 (donor T-cells) in combination with
APC–anti-CD4 and PE–anti-CD25.
All fluorochrome-conjugated MoAbs were purchased
from BD Pharmingen (San Diego, CA). Flow cytometry was
done using a Becton Dickinson FACScan or FACSCalibur
flow cytometer (BD Biosciences). Five to 50 × 104 events
were collected for 2- and 3-color analyses. Data were ana-
lyzed with FlowJo software (Tree Star, San Carlos, CA).
Statistics
Survival curves were compared using the log-rank test.
Spleen and thymus cell numbers; percentages of splenic
B-cells, T-cells, Mac-1+ cells, and CD4+CD25+ cells; and
percentages of infused donor T-cells in blood samples were
compared using the Student t test.
RESULTS
CD4+ Regulatory T-cells Are Important to the
Suppression of GVH Reactivity after DLI
Initial experiments were done to conﬁrm previous ﬁnd-
ings that Thy1+CD4+ T-cells of donor origin suppressed
GVH reactivity after DLI. The results from 20 indepen-
dent experiments examining the effect of eliminating donor
BM–derived Thy1+ T-cells before DLI were combined
(Figure 2A). Recipient AKR mice were given lethal TBI
(1100 cGy), received transplants of 107 T-cell–depleted B6
BM cells, then randomized into 3 groups: (a) mice that
received no additional treatment (BM only), (b) mice given
DLI with 3 × 107 Thy1.1+ donor (B6.PL-Thy1a) spleen cells
28 days after BM transplantation, and (c) mice depleted of
donor BM–derived T-cells before DLI by treatment with
anti-Thy1.2 MoAb (–4 and –2 days before DLI). Use of
lethal TBI resulted in rapid and complete donor engraft-
ment in all cell lineages except for the T-cell compartment,
which contained a mixture of donor and residual host T-cells
(data not shown). Overall survival of mice receiving trans-
plants of BM alone was 91% (Figure 2A). The mice main-
tained or gained body weight following early conditioning-
related body weight loss (Figure 2B), indicating little or no
GVHD. Mice given DLI on day 28 had worse overall sur-
vival outcomes than did mice not given DLI (81% versus
91%), but the difference was not statistically significant
(Figure 2A). However, DLI-treated mice had some GVHD,
as indicated by marked body weight loss after DLI (Figure
2B). Mice that were depleted of BM-derived donor T-cells
before DLI developed severe GVHD, and only 1% (1/76)
survived until day 85 after BMT (Figure 2A). Clinical onset
of GVHD was accompanied by a sharp loss in body weight
(Figure 2B), and the majority of recipients died within 10 to
20 days after DLI.
In the next series of experiments, to assess whether BM-
donor–derived CD4+ and/or CD8+ cells were essential for
preventing GVHD after DLI therapy, we transplanted BM
from CD4-KO or CD8-KO B6 mice into host mice. The
dose of donor cells from normal mice given as DLI was 6 ×
107 splenocytes, and the time of DLI was day 35 after BMT.
These parameters were changed to determine whether
higher numbers of DLI cells would overwhelm the effect of
CD4+ regulatory T-cells on suppression of GVHD. Control
mice received transplants of normal BM plus DLI. Mice
receiving transplants of BM alone (no DLI) were included
as GVH-negative controls. Transplantation with CD4-KO
or CD8-KO BM did not adversely affect engraftment of
donor hematopoietic cells (data not shown). The survival
rate of mice receiving transplants of CD8-KO BM and
given DLI was not signiﬁcantly different from that of mice
receiving transplants of normal BM and given DLI (Fig-
ure 3), a result indicating that donor CD8+ cells were not
involved in suppression of GVHD after DLI. In contrast,
the survival rate of mice receiving transplants of BM from
CD4-KO donors and given DLI was significantly lower
Figure 3. Conﬁrmation that donor Thy1+ regulatory T-cells include CD4+ cells but not CD8+ cells. Irradiated recipient AKR mice received trans-
plants of 107 BM cells from normal, CD4-KO, or CD8-KO C57BL/6 donor mice. GVH-negative controls consisted of mice that received trans-
plants of normal BM only (no DLI). The other groups were all given DLI with 6 × 107 normal Thy1.1+ donor (B6.PL-Thy1a) spleen cells on day 35
post-BMT. Survival curves are the combined data of 3 independent experiments.
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than that of mice receiving transplants of normal BM, a
result suggesting that donor BM–derived CD4+ regulatory
T-cells contributed to suppression of DLI-induced GVH
reactivity. Results of these experiments conﬁrm and extend
our previous report that donor Thy1+CD4+ regulatory
T-cells suppress GVH reactivity after DLI [23].
CD25+ Regulatory T-Cells Are Important to the
Suppression of GVH Reactivity after DLI
To assess the role of CD25+ regulatory T-cells in sup-
pression of GVH reactivity after DLI, we transplanted BM
from CD25-KO mice into recipient AKR mice. If CD25+
regulatory T-cells were involved, then mice undergoing
reconstitution with CD25-KO BM would develop more
severe GVHD after DLI than mice receiving transplants of
normal BM. Control groups included mice receiving
transplants of normal BM or CD25-KO BM alone (GVH-
negative controls), as well as a small group of mice receiving
transplants of normal BM but depleted of donor regulatory
T-cells by treatment with anti-Thy1.2 MoAb before DLI
(GVH-positive controls). For DLI, mice were given a single
IV injection of 3 × 107 normal Thy1.1+ donor splenocytes
on day 28 posttransplantation. All mice in the experiments
were tested for engraftment status on day 27 after BMT to
ensure engraftment of donor cells. Combined survival data
from 3 experiments are shown in Figure 4A, and body
weight curves from 1 representative experiment are shown
in Figure 4B.
Survival of GVH-negative controls that received trans-
plants of normal or CD25-KO BM alone (no DLI) was
Figure 4. CD25+ cells are involved in suppression of alloreactivity after DLI. Irradiated AKR recipients received transplants of 107 BM cells from
normal or CD25-KO C57BL/6 donor mice. GVH-negative controls consisted of mice that received transplants of normal BM or CD25-KO BM
(no DLI). Mice treated with anti-Thy1.2 MoAb to eliminate donor regulatory cells were injected with 1 mg of antibody twice (days –4 and –2)
before DLI. Groups of recipients given a DLI were injected with 3 × 107 normal Thy1.1+ donor (B6.PL-Thy1a) spleen cells on day 28 post-BMT.
The mice were followed for survival (A) and body weight change (B). Survival curves are the combined results of 3 independent experiments, and
body weight curves are results from 1 representative experiment.
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>93% (Figure 4A), and body weights of these mice remained
at or near pretransplantation levels (Figure 4B). In contrast,
GVH-positive control mice, depleted of regulatory T-cells
before DLI, all died with clinical evidence of severe GVHD
(Figure 4, open triangles). Because mice that received trans-
plants of CD25-KO BM and DLI had a signiﬁcantly lower
survival rate than did mice that received transplants of nor-
mal BM and DLI (17% versus 83%, Figure 4A), donor
BM–derived CD25+ T-cells were implicated in suppression
of DLI-induced GVH reactivity. The lower survival rate in
DLI-treated mice that received transplants of CD25-KO
BM was paralleled by increased body weight loss (Figure 4B).
Blood samples were obtained from some mice 10 days after
DLI to examine the percentages of circulating DLI-derived
donor T-cells by flow cytometry. Donor T-cells derived
from the DLI (Thy1.1+) could be distinguished from BM-
derived donor T-cells (Thy1.2+) with donor-speciﬁc MHC
class I–speciﬁc MoAb and anti-Thy1.1 MoAb. The periph-
eral blood of mice that received transplants of CD25-KO
BM contained significantly higher percentages of DLI-
derived donor T-cells than did peripheral blood of mice that
received transplants of normal BM (20% versus 6%; P <
.05), suggesting that the infused donor T-cells had expanded
more in recipients of CD25-KO BM.
CD28, but Not CD40L, Is Necessary for the
Generation of Donor-Derived Regulatory T-Cells 
that Suppress GVH Reactivity after DLI
To address the importance of CD28 and CD40L mole-
cules for the generation of regulatory T-cells, we trans-
planted T-cell–depleted BM from CD28-KO, CD40L-KO,
or normal B6 mice into lethally irradiated recipient AKR
mice. Both CD28-KO and CD40L-KO mice, used as BM
donors, had fewer CD4+CD25+ T-cells, as indicated by a
significantly decreased percentage of CD4+CD25+ T-cells
found in their spleens compared to the percentage found
in normal B6 mice (Table 1). Notably, the decrease in
CD4+CD25+ T-cells was greater in CD28-KO mice. On day
28 after BMT, DLI as a single injection of 3 × 107 normal
Thy1.1+ B6 splenocytes was administered to some of the
mice that had received transplants. Controls included mice
that received BM transplants only (no DLI) and mice
depleted of Thy1.2+ donor regulatory T-cells by adminis-
tration of anti-Thy1.2 MoAb before DLI. Some BM
chimeras were killed at the time of DLI to assess chimerism
and immune reconstitution in the spleen and thymus
(Table 2). For reconstitution, recipients of CD28-KO or
CD40L-KO BM were administered donor hematopoietic
cells at levels similar to those administered to recipients of
normal BM (data not shown). Spleen and thymus cellulari-
ties of recipients of CD28-KO or CD40L-KO BM also
were similar to those of recipients of normal B6 BM (Table
2). The percentages of splenic B-cells, T-cells, and Mac-1+
cells (macrophages/monocytes) in these BM chimeras were
not significantly different from one another (Table 2).
Collectively, these data indicated that BMT with CD28-
KO or CD40L-KO BM did not alter donor engraftment or
immune reconstitution.
The spleens of BM chimeras analyzed on day 28 after
BMT were also examined for CD4+CD25+ cell content
(Table 3). Although the non–T-cell compartments were
completely donor reconstituted, the T-cells in these mice
remained 32% to 49% of host origin. We examined the
donor-derived and host T-cell compartments separately for
CD25 expression. Recipients of CD28-KO BM had a signiﬁ-
cantly lower percentage of donor-derived splenic CD4+ cells
that were CD25+ than did recipients of normal BM or
CD40L-KO BM (Table 3). In contrast, CD25 expression on
donor-derived CD4+ cells in recipients of CD40L-KO BM
was not signiﬁcantly different from that in recipients of nor-
mal BM. CD25 expression on host CD4+ T-cells was the
same in all 3 groups of BM chimeras (Table 3).
Figure 5A shows the combined survival data from 3 inde-
pendent experiments in which recipient AKR mice received
transplants of CD28-KO BM with or without DLI. Greater
than 90% of control mice that received transplants of BM
only (normal or CD28 KO) survived long-term (Figure 5A,
circles), and body weights of these mice remained above
pretransplantation levels (Figure 5B). In contrast, mice
depleted of regulatory T-cells before DLI (by treatment with
Table 1. Percentages of CD4+CD25+ T-Cells Are Lower in Spleens of
CD28-KO and CD40L-KO BM Donors than in Spleens of Normal BM
Donors
BM Donors* n % of CD25+ Splenic CD4+ Cells
Normal 4 9.7 ± 1.0
CD28 KO 4 2.6 ± 0.3†
CD40L KO 5 5.2 ± 1.3†
*Spleens of BM donors used in the experiments in Figures 5 and 6
were analyzed by ﬂow cytometry for CD4+CD25+ T-cell content.
†P < .05 compared to normal BM donors.
Table 2. Immune Reconstitution in Recipients of CD28-KO or CD40L-KO BM Is Not Different from Immune Reconstitution in Recipients of Normal BM
Splenocytes, %*
BM Chimeras† n Spleen Size, ×107 Thymus Size, ×107 B-Cells T-Cells Mac-1+ Cells
Normal 9 4.3 ± 1.4 10.1 ± 5.7 66.8 ± 14.0 22.9 ± 9.3 8.0 ± 3.4
CD28 KO 7 6.2 ± 1.5‡ 7.0 ± 1.9 73.1 ± 2.2 20.1 ± 3.8 5.2 ± 1.2
CD40L KO 10 5.7 ± 1.0‡ 8.9 ± 2.8 74.6 ± 3.0 20.0 ± 2.7 5.4 ± 1.8
*Spleens and thymuses were isolated on day 28 after BMT from AKR recipients that had received transplants of BM from normal, CD28-KO, or
CD40L-KO C57BL/6 mice (see “Materials and Methods” for details).
†The splenic B-cells and Mac-1+ cells from all chimeras were completely of donor origin. In contrast, the T-cells from all chimeras consisted of
both donor and residual host cells (51%-68% donor cells).
‡P < .05 compared to recipients of normal BM.
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anti-Thy1.2 MoAb) developed severe GVHD after DLI
(Figure 5, triangles). Mice receiving transplants of normal
BM and given DLI had a lower survival rate (76%) than did
recipients of BM only (92%) (Figure 5A) and had increased
body weight loss (Figure 5B). However, mice receiving trans-
plants of CD28-KO BM and given DLI developed severe
and lethal GVHD (Figure 5). The survival rate for this
group was not significantly different from that of control
mice depleted of regulatory T-cells with anti-Thy1.2 MoAb.
The similarities in survival rates in these 2 groups were also
reﬂected by similar patterns in body weight loss after DLI.
Blood samples were collected from some DLI-treated mice
7 days after DLI to assess the percentage of circulating DLI-
derived donor T-cells. The blood of mice that received
transplants of CD28-KO BM contained a significantly
higher percentage of infused donor T-cells than did the
blood of mice that received transplants of normal BM (15%
versus 4%; P < .05), demonstrating a correlation between
increased percentages of infused donor T-cells and increased
GVH-associated mortality. These results indicate that CD28
is critical for the generation of regulatory T-cells that sup-
press DLI-induced GVH reactivity.
Figure 6A shows survival data from an experiment in
which recipient AKR mice were given transplants of
CD40L-KO BM. Data from GVH-negative controls (mice
given BM transplants only) and GVH-positive controls
(mice depleted of donor regulatory T-cells with anti-Thy1.2
MoAb before DLI) are also shown. The key comparison is
between mice receiving normal BM transplants and given
DLI and mice receiving CD40L-KO BM transplant and
given DLI. Long-term survival rates were not signiﬁcantly
different between these 2 experimental groups (Figure 6A),
and body weight curves were similar (Figure 6B). Blood
samples were collected from some DLI-treated mice 7 days
after DLI to examine percentages of circulating infused
donor T-cells. The percentages in the blood of mice that
received CD40L-KO BM transplants were not different
from percentages in mice that received normal BM (1.8%
versus 2.1%, respectively). These results suggest that
CD40-CD40L interactions are not involved in generation
(or activation) of donor regulatory T-cells that suppress
GVHD after DLI.
DISCUSSION
In the current study, we showed that CD25+ cells of
donor origin are critical for the suppression of GVH reactiv-
ity after DLI (Figure 4). These cells may be involved in the
establishment and maintenance of donor-host tolerance after
allogeneic BMT. In the present study, we did not directly
prove that the CD25+ cells were CD4+, but several lines of
indirect evidence suggest that they were. First, the pattern of
mortality and overall survival rates after DLI were similar in
mice receiving transplants of either CD25-KO (Figure 4) or
CD4-KO BM (Figure 3 and [23]). Second, CD4+CD25+ reg-
ulatory T-cells are generated in the thymus [7,8], and we
previously reported that the regulatory T-cells in our DLI
model are produced by the donor-repopulated host thymus
[23]. Third, others have reported that the majority of T-cells
that constitutively express CD25 (>90%) coexpress CD4
[1,2]. Likewise, most CD25+ cells present in our BM
chimeras at the time of DLI were CD4+, suggesting that the
Thy1.2+ regulatory T-cells were most likely CD4+CD25+.
Because CD28-B7 costimulatory interactions have
been shown by others to be important in generation of
CD4+CD25+ regulatory T-cells [9], we tested whether elimi-
nation of CD28 expression on donor T-cells interfered with
the generation of regulatory T-cells in our DLI model. If
CD28 was important for generation of the CD25+ regula-
tory T-cells, then the survival of DLI-treated mice that
received transplants of CD28-KO BM should be similar to
that of CD25-KO BM chimeras. However, none of the mice
given transplants of BM from CD28-KO donors survived
DLI, whereas 17% of those given transplants of BM from
CD25-KO donors did (P = .0086). The survival and body
weight curves of DLI-treated mice that received transplants
of CD28-KO BM were nearly identical to those of mice
depleted of “all” Thy1+ regulatory T-cells, suggesting that
elimination of CD28 affected the generation of both
CD4+CD25+ and the putative CD4–CD8– DN regulatory
T-cells. Salomon et al. [9] previously showed that both
CD28-KO and B7-KO mice have a profound deﬁciency of
CD4+CD25+ cells. We conﬁrmed this ﬁnding in our CD28-
KO BM donors (Table 1). Transplantation with BM from
CD28-KO mice resulted in a deficiency of splenic donor-
derived CD4+CD25+ cells after BMT (Table 3). We also
found a deficiency of thymic CD4+CD8–CD25+ cells in
these chimeras (data not shown), suggesting that there was a
defect in thymic generation of these cells. Takahashi and
coworkers found that the small numbers of CD4+CD25+
cells in CD28-KO mice are potently suppressive [24], indi-
cating that CD28 expression on CD25+ regulatory T-cells is
not required for suppressive activity. Collectively, these
observations suggest that CD28 is important for the genera-
tion of CD25+ regulatory T-cells but not for functional
activity. There may be a threshold number of CD4+CD25+
cells necessary to effectively suppress GVHD after DLI.
It has been shown that small numbers of T-cells injected
into T-cell–deficient syngeneic mice expand to achieve
homeostasis [25]. Because the mice in our DLI model are
mixed T-cell chimeras, treatment with anti-Thy1.2 MoAb
(before DLI) results in the depletion of 50% to 70% of the
total T-cells. We interpret our data to indicate that the
DLI-induced GVHD after depletion of the Thy1.2+ cells in
vivo was due to the removal of regulatory T-cells. However,
Table 3. At the Time of DLI, Chimeras Receiving Transplants of CD28-KO
BM Had a Signiﬁcantly Lower Percentage of Splenic Donor CD4+ Cells that
Were CD25+ than Did Chimeras Receiving Transplants of Normal BM or
CD40L-KO BM
% of CD25+ % of CD25+
BM Chimeras* n Donor CD4+ Cells Host CD4+ Cells
Normal 9 5.3 ± 1.9 12.4 ± 2.0
CD28 KO 7 2.6 ± 1.1† 11.6 ± 1.9
CD40L KO 10 4.6 ± 1.3 12.2 ± 2.3
*Spleens were isolated on day 28 after BMT from AKR recipients
that had received transplants of BM from normal, CD28-KO, or
CD40L-KO C57BL/6 mice. T-cell chimerism in the spleens of all BM
recipients on day 28 was mixed (51% to 68% donor T-cells).
†P < .05 compared to chimeras receiving transplants of normal BM
or CD40L-KO BM.
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an alternative hypothesis for the heightened DLI-induced
GVHD after Thy1.2+ T-cell depletion is that the induced
T-cell deﬁciency creates a favorable environment for expan-
sion of DLI T-cells and, consequently, heightened GVH
reactivity. This hypothesis can be excluded for the following
reason: mice given transplants of CD28-KO BM developed
severe GVHD after DLI, but they did not have altered T-cell
reconstitution at the time of DLI. The percentage of
peripheral (splenic) T-cells was the same as that in mice
given transplants of normal BM (Table 2). Although there
were decreased percentages of donor CD4+CD25+ cells in
mice given transplants of CD28-KO BM (Table 3), this
decrease did not affect the overall T-cell number. These
data argue against the T-cell–deﬁciency hypothesis and sup-
port our assertion that the increased rate of GVHD in mice
given transplants of CD28-KO BM was due to a deﬁciency
in regulatory T-cells.
Data from others has indicated that CD40-CD40L
interactions also are important for generation of CD4+CD25+
regulatory cells [10]. Kumanogoh and colleagues showed
that splenocytes from CD40-KO mice have an 80% reduc-
tion in CD4+CD25+ T-cell numbers [10]. We formulated a
hypothesis based on these data, that if donor T-cells were
incapable of expressing the ligand for CD40 in our DLI
model, then we would see increased DLI-induced mortality.
However, in recipients of CD40L-KO BM, survival rates
after DLI were no different from those in recipients of nor-
mal BM that gives rise to regulatory T-cells (Figure 6A).
Figure 5. CD28 is necessary for the generation of donor-derived Thy1+ regulatory T-cells. Irradiated recipient AKR mice received transplants of
107 BM cells from normal or CD28-KO C57BL/6 donor mice. GVH-negative controls consisted of mice that received transplants of normal BM or
CD28-KO BM (no DLI). GVH-positive controls (regulatory T-cells depleted) consisted of mice treated with anti-Thy1.2 MoAb (0.5 mg IP) 4 and
2 days before DLI. DLI was administered as a single IV injection of 3 × 107 normal Thy1.1+ donor (B6.PL-Thy1a) spleen cells on day 28 post-BMT.
The mice were followed for survival (A) and body weight change (B). Survival curves are the combined results of 3 independent experiments, and
body weight curves are the result of 1 representative experiment.
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The CD40L-KO BM donors used in our experiments had
decreased percentages of splenic CD4+CD25+ T-cells
(approximately 50% of normal, Table 1), but spleens of BM
chimeras given transplants of CD40L-KO BM did not
have decreased percentages of donor-derived CD25+ cells
(Table 3). Thus, our data indicate that CD40L is not
involved in generation of the regulatory T-cells that sup-
press DLI-induced GVHD. Reduction in CD4+CD25+
T-cell numbers is apparently more profound in CD40-
deficient mice than in CD40L-deﬁcient mice [10]. The rea-
son for this difference is not known.
Our data are most consistent with the hypothesized
presence of at least 2 populations of regulatory T-cells
involved in suppression of GVHD after DLI. Both popula-
tions are Thy1+ αβTCR+ [23] and natural killer (NK)1.1–
[26]. Based on the indirect evidence cited above, the ﬁrst of
these populations appears to comprise CD4+CD25+ T-cells.
However, because the survival rates for DLI-treated mice
given transplants of CD25-KO or CD4-KO BM were
significantly higher than the survival rates of mice depleted
of Thy1.2+ cells before DLI (Figures 3 and 4), we speculate
that a second population of Thy1+ cells (CD4– and CD25–)
also may be involved in the suppression of GVH reactivity.
Because donor CD8+ T-cells do not appear to be involved
(Figure 3 and [23]), the second regulatory population may
consist of CD4–CD8– DN T-cells. Such a finding would
not be unexpected, because a variety of T-cell populations
have been shown to be immunosuppressive, including
CD3+NK1.1– DN T-cells [27,28]. In normal mice, 1% to
5% of peripheral T-cells are DN [29]. It has been suggested
that DN cells are derived from CD8+ T-cells [30,31]. How-
ever, if DN cells are involved in suppression of GVHD after
DLI in our models, our results indicate that they are not
derived from CD8+ cells, because mice given transplants of
Figure 6. CD40L is not needed for the generation of donor regulatory T-cells. Irradiated recipient AKR mice received transplants of 107 BM cells
from normal or CD40L-KO C57BL/6 donor mice. GVH-negative controls consisted of mice that received transplants of normal BM or CD40L-
KO BM (no DLI). GVH-positive controls (regulatory T-cells depleted) consisted of mice treated with anti-Thy1.2 MoAb (0.5 mg IP) 4 and 2 days
before DLI. DLI was administered as a single IV injection of 3 × 107 normal Thy1.1+ donor (B6.PL-Thy1a) spleen cells on day 28 post-BMT. The
mice were followed for survival (A) and body weight change (B). The survival curves and body weight curves are from a single experiment.
B. D. Johnson et al.
534
CD8-KO BM did not develop severe GVHD after DLI
(Figure 3). CD4+CD25+ cells isolated from mice given DLI
were immunosuppressive in vitro (data not shown). Whether
suppressive activity is present in CD4–CD8– T-cells has not
yet been determined.
In summary, we have shown that CD25+ T-cells of
donor origin suppress in vivo alloreactivity after DLI in
mice. Collectively, the evidence suggests that these cells are
similar, if not identical, to the thymus-derived CD4+CD25+
regulatory T-cells that have been shown by several investi-
gators to be important in the suppression of autoimmune
diseases. Our data also suggest that a second regulatory cell
population comprised of CD4–CD8– DN T-cells may be
involved. Both regulatory cell populations are thymus
derived, and CD28 is critical for their generation. Current
efforts are focusing on isolation and ex vivo expansion of
these regulatory cells for adoptive transfer to secondary
recipients. Recent data from Taylor et al. [22] suggests that
CD4+CD25+ regulatory cells can be expanded ex vivo and
adoptively transferred in vivo to inhibit GVHD. Because
the development of GVHD after DLI is still a significant
problem [32], demonstration that adoptively transferred
regulatory T-cells suppress GVH reactivity in our experi-
mental DLI model could have significant implications for
the clinical use of these cells in the treatment/prevention of
GVHD after DLI.
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